These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 16504307)

  • 21. CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism.
    Yang T; Wall EM; Milne K; Theiss P; Watson P; Nelson BH
    Clin Cancer Res; 2007 Dec; 13(23):7172-80. PubMed ID: 18056198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells.
    Sabel MS; Arora A; Su G; Mathiowitz E; Reineke JJ; Chang AE
    Surgery; 2007 Nov; 142(5):749-60. PubMed ID: 17981196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
    Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
    Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
    Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
    Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-priming of CD8+ T cells by viral and tumor antigens is a robust phenomenon.
    Chen W; Masterman KA; Basta S; Haeryfar SM; Dimopoulos N; Knowles B; Bennink JR; Yewdell JW
    Eur J Immunol; 2004 Jan; 34(1):194-9. PubMed ID: 14971045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity.
    Balkow S; Loser K; Krummen M; Higuchi T; Rothoeft T; Apelt J; Tuettenberg A; Weishaupt C; Beissert S; Grabbe S
    Exp Dermatol; 2009 Jan; 18(1):78-87. PubMed ID: 19054060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin-2 activated microglia engulf tumor infiltrating T cells in the central nervous system.
    Tamakawa N; Saio M; Suwa T; Ohe N; Yoshimura S; Iwama T; Shinoda J; Sakai N; Takami T
    Int J Mol Med; 2004 Apr; 13(4):497-503. PubMed ID: 15010848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.
    Fecci PE; Sweeney AE; Grossi PM; Nair SK; Learn CA; Mitchell DA; Cui X; Cummings TJ; Bigner DD; Gilboa E; Sampson JH
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4294-305. PubMed ID: 16857805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.
    Kohlmeyer J; Cron M; Landsberg J; Bald T; Renn M; Mikus S; Bondong S; Wikasari D; Gaffal E; Hartmann G; Tüting T
    Cancer Res; 2009 Aug; 69(15):6265-74. PubMed ID: 19622767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity.
    Ramirez-Montagut T; Turk MJ; Wolchok JD; Guevara-Patino JA; Houghton AN
    Oncogene; 2003 May; 22(20):3180-7. PubMed ID: 12789294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer immunotherapy by interleukin-21: potential treatment strategies evaluated in a mathematical model.
    Cappuccio A; Elishmereni M; Agur Z
    Cancer Res; 2006 Jul; 66(14):7293-300. PubMed ID: 16849579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells.
    Iwai Y; Terawaki S; Honjo T
    Int Immunol; 2005 Feb; 17(2):133-44. PubMed ID: 15611321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
    Bracci L; Moschella F; Sestili P; La Sorsa V; Valentini M; Canini I; Baccarini S; Maccari S; Ramoni C; Belardelli F; Proietti E
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):644-53. PubMed ID: 17255288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Xenogeneic melanoma-related antigen elicits anti-tumor immune response, companied by autoimmune injury].
    Tan XH; Wan YH
    Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(23):1596-600. PubMed ID: 16185524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL-21 and IL-15 cytokine DNA augments HSV specific effector and memory CD8+ T cell response.
    Rodrigues L; Nandakumar S; Bonorino C; Rouse BT; Kumaraguru U
    Mol Immunol; 2009 Apr; 46(7):1494-504. PubMed ID: 19233474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor-derived interleukin-4 reduces tumor clearance and deviates the cytokine and granzyme profile of tumor-induced CD8+ T cells.
    Olver S; Groves P; Buttigieg K; Morris ES; Janas ML; Kelso A; Kienzle N
    Cancer Res; 2006 Jan; 66(1):571-80. PubMed ID: 16397274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolonged culture of vaccine-primed lymphocytes results in decreased antitumor killing and change in cytokine secretion.
    Sussman JJ; Parihar R; Winstead K; Finkelman FD
    Cancer Res; 2004 Dec; 64(24):9124-30. PubMed ID: 15604282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In situ tumor ablation creates an antigen source for the generation of antitumor immunity.
    den Brok MH; Sutmuller RP; van der Voort R; Bennink EJ; Figdor CG; Ruers TJ; Adema GJ
    Cancer Res; 2004 Jun; 64(11):4024-9. PubMed ID: 15173017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.